JP2021513998A - 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 - Google Patents

鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 Download PDF

Info

Publication number
JP2021513998A
JP2021513998A JP2020544420A JP2020544420A JP2021513998A JP 2021513998 A JP2021513998 A JP 2021513998A JP 2020544420 A JP2020544420 A JP 2020544420A JP 2020544420 A JP2020544420 A JP 2020544420A JP 2021513998 A JP2021513998 A JP 2021513998A
Authority
JP
Japan
Prior art keywords
bupropion
dosage form
administered
dextromethorphan
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544420A
Other languages
English (en)
Japanese (ja)
Inventor
タビュトー、ヘリオット
Original Assignee
アクスサム セラピューティクス インコーポレイテッド
アクスサム セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクスサム セラピューティクス インコーポレイテッド, アクスサム セラピューティクス インコーポレイテッド filed Critical アクスサム セラピューティクス インコーポレイテッド
Publication of JP2021513998A publication Critical patent/JP2021513998A/ja
Priority to JP2022124557A priority Critical patent/JP2022153638A/ja
Priority to JP2024041381A priority patent/JP2024075655A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020544420A 2018-02-23 2019-02-25 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形 Pending JP2021513998A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022124557A JP2022153638A (ja) 2018-02-23 2022-08-04 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法
JP2024041381A JP2024075655A (ja) 2018-02-23 2024-03-15 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US62/634,718 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US62/794,469 2019-01-18
US201962809480P 2019-02-22 2019-02-22
US62/809,480 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022124557A Division JP2022153638A (ja) 2018-02-23 2022-08-04 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法
JP2024041381A Division JP2024075655A (ja) 2018-02-23 2024-03-15 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Publications (1)

Publication Number Publication Date
JP2021513998A true JP2021513998A (ja) 2021-06-03

Family

ID=67688503

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544420A Pending JP2021513998A (ja) 2018-02-23 2019-02-25 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形
JP2022124557A Pending JP2022153638A (ja) 2018-02-23 2022-08-04 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法
JP2024041381A Pending JP2024075655A (ja) 2018-02-23 2024-03-15 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022124557A Pending JP2022153638A (ja) 2018-02-23 2022-08-04 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法
JP2024041381A Pending JP2024075655A (ja) 2018-02-23 2024-03-15 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Country Status (19)

Country Link
EP (1) EP3755312A4 (enExample)
JP (3) JP2021513998A (enExample)
KR (3) KR20210003091A (enExample)
CN (2) CN120827545A (enExample)
AU (3) AU2019223187B2 (enExample)
BR (1) BR112020017179A2 (enExample)
CA (1) CA3092076A1 (enExample)
CL (1) CL2020002166A1 (enExample)
CR (1) CR20200415A (enExample)
EC (1) ECSP20060179A (enExample)
IL (2) IL276871B2 (enExample)
MA (1) MA51914A (enExample)
MX (2) MX2020008704A (enExample)
MY (1) MY202993A (enExample)
NI (1) NI202000056A (enExample)
NZ (1) NZ767378A (enExample)
PE (1) PE20211752A1 (enExample)
SG (1) SG11202008056SA (enExample)
WO (1) WO2019165379A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022153638A (ja) * 2018-02-23 2022-10-12 アクスサム セラピューティクス インコーポレイテッド 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
CA3287347A1 (en) * 2019-09-20 2025-11-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003529563A (ja) * 2000-02-22 2003-10-07 セプラコア インコーポレーテッド ビュープロピオン代謝産物並びにその合成および使用方法
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2483499A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (+)-bupropion
SI1575565T1 (sl) * 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
MX2020008704A (es) * 2018-02-23 2020-12-07 Axsome Therapeutics Inc Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003529563A (ja) * 2000-02-22 2003-10-07 セプラコア インコーポレーテッド ビュープロピオン代謝産物並びにその合成および使用方法
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J CLIN PHARMACOL, vol. 48, JPN6021032200, 2008, pages 464 - 474, ISSN: 0004744663 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022153638A (ja) * 2018-02-23 2022-10-12 アクスサム セラピューティクス インコーポレイテッド 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形および方法

Also Published As

Publication number Publication date
MX2020008704A (es) 2020-12-07
JP2024075655A (ja) 2024-06-04
ECSP20060179A (es) 2020-12-31
EP3755312A4 (en) 2022-03-16
AU2019223187B2 (en) 2022-07-28
PE20211752A1 (es) 2021-09-06
JP2022153638A (ja) 2022-10-12
AU2022204521B2 (en) 2024-09-05
IL313368A (en) 2024-08-01
IL276871B2 (en) 2024-11-01
KR20230075531A (ko) 2023-05-31
WO2019165379A1 (en) 2019-08-29
NZ767378A (en) 2024-03-22
MY202993A (en) 2024-05-31
CL2020002166A1 (es) 2020-10-23
IL276871B1 (en) 2024-07-01
IL276871A (en) 2020-10-29
CR20200415A (es) 2021-02-03
AU2022204521A1 (en) 2022-07-21
MA51914A (fr) 2020-12-30
KR20210003091A (ko) 2021-01-11
CN120827545A (zh) 2025-10-24
AU2019223187A1 (en) 2020-09-17
NI202000056A (es) 2021-01-11
CN112087999A (zh) 2020-12-15
EP3755312A1 (en) 2020-12-30
SG11202008056SA (en) 2020-09-29
BR112020017179A2 (pt) 2020-12-22
KR20240091043A (ko) 2024-06-21
MX2023009281A (es) 2023-08-17
CA3092076A1 (en) 2019-08-29
AU2024205858A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
US20210196704A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20210177834A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
JP2021513998A (ja) 鏡像異性体的に濃縮された、または鏡像異性体的に純粋なブプロピオンの剤形
US20190216800A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20190216801A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US12377091B2 (en) Compounds and combinations thereof for treating neurological and psychiatric conditions
US11344544B2 (en) Bupropion as a modulator of drug activity
US20220313689A1 (en) Bupropion as a modulator of drug activity
US10695304B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
JP2022516361A (ja) うつ病の治療のためのデキストロメトルファンおよびブプロピオンの組み合わせ
US11179352B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US12433884B2 (en) Compounds and combinations thereof for treating neurological and psychiatric conditions
US20220249405A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40043597A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
JP2024059812A (ja) 鏡像異性体的に濃縮された、または純粋なブプロピオンの剤形および方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220804

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220816

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240315